Minimally Invasive Micro Sclerostomy: 3 Years Follow Ups
Published 2023 - 41st Congress of the ESCRS
Reference: PO0873 | DOI: 10.82333/gdc1-ja46
Authors: Lilit Albert Voskanyan* 1 , Astghik Ghazaryan 2 , Hovsep Miroyan 3 , Vahan Papoyan 2
1Glaucoma Chief of Dept,S.V.Malayan's Eye Center, Chief of Ophthalmology at Yerevan State Medical Universityr,Yerevan,Armenia, 2Glaucoma,S.V.Malayan's Eye Center,Yerevan,Armenia, 3Director,S.V.Malayan's Eye Center,Yerevan,Armenia
To provide three years follow-up data on superonasal MIMS® (minimally invasive micro sclerostomy) operation in open angle glaucoma Caucasian patients.
Department of Glaucoma, Malayan medical center, Yerevan, Armenia. Long term (3 years) results from participants in an already completed and reported one year study.
The MIMS® device (Sanoculis, Israel) automatically creates by an ab-interno approach, a circa 1 mm long, drainage channel of circa 100 microns diameter at the superonasal (SN) sclera-corneal junction. It connects the anterior chamber with the subconjunctival space to perform a filtering operation. All patients who were termed successful at one year after MIMS® procedure or were termed a failure because of higher than target IOP however were not given a chance to add medication, were invited to participate in a long term success evaluation study.
N=40, follow-up: 36 months, surgery length: 2:01±0:41 minutes, preoperative IOP (intraocular pressure) 27.3±3.7 mmHg, postoperative IOP 17.3±5.3 mmHg, reduction in IOP 38.0%, reduction in medications 70.0% (from 1.7±0.8 to 0.5±0.88), reversible adverse events 13%, irreversible adverse events 0%, qualified success 56.3%, complete success 42.8%. Success rate (FDA definition): at least 20% reduction in IOP on same number or less (qualified success) or no (complete success) medications. Success rate (FDA definition): at least 20% reduction in IOP on same number or less (qualified success) or no (complete success) medications.
The minimally invasive anti-glaucoma surgical procedure, done with the MIMS® device, was found satisfactory in open angle glaucoma patients after 3 years follow-up. The efficacy and safety results were found similar to other filtration procedures. However, the MIMS® procedure is simpler and quicker.